Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Multiple Sclerosis Relapsing Remitting”

721 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 721 results

Not applicableLooking for participantsNCT05177523
What this trial is testing

Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis (MS)Relapsing-remitting Multiple Sclerosis (RRMS)Secondary-progressive Multiple Sclerosis (SPMS)+1 more
University Hospital, Basel, Switzerland 300
Not applicableStudy completedNCT01626248
What this trial is testing

Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control

Who this might be right for
Multiple Sclerosis
John F. Foley, MD 164
Not applicableLooking for participantsNCT07318129
What this trial is testing

Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis (RRMS)
Glostrup University Hospital, Copenhagen 220
Not applicableStudy completedNCT03134573
What this trial is testing

Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study

Who this might be right for
Multiple Sclerosis
Bayer 96
Not applicableUnknownNCT02769767
What this trial is testing

Polymorphisms of Interleukins, Glypican, and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis.

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Instituto Jalisciense de Cancerologia 500
Post-approval studies (Phase 4)Looking for participantsNCT04480853
What this trial is testing

Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Novartis Pharmaceuticals 30
Not applicableStudy completedNCT04655222
What this trial is testing

Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
Biogen 470
Not applicableEnded earlyNCT02580669
What this trial is testing

Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis

Who this might be right for
Progressive Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
University Hospital, Montpellier 70
Early research (Phase 1)Study completedNCT00559702
What this trial is testing

Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)

Who this might be right for
Relapsing-Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis
Biogen 76
Not applicableStudy completedNCT06915272
What this trial is testing

Effects of Sailing and Cooing in the Quality of Life of Multiple Sclerosis Individuals

Who this might be right for
Multiple Sclerosis (MS) - Relapsing-remitting
University of Thessaly 45
Not applicableEnded earlyNCT02323269
What this trial is testing

Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)

Who this might be right for
Multiple Sclerosis, Relapsing-RemittingRelapsing-Remitting Multiple Sclerosis
Biogen 24
Post-approval studies (Phase 4)Study completedNCT00246324
What this trial is testing

Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Louisiana State University Health Sciences Center Shreveport 16
Testing effectiveness (Phase 2)Study completedNCT00288626
What this trial is testing

High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
National Institute of Allergy and Infectious Diseases (NIAID) 25
Testing effectiveness (Phase 2)Study completedNCT01890655
What this trial is testing

Extension Study of MT-1303

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Tanabe Pharma Corporation 367
Large-scale testing (Phase 3)Study completedNCT00027300
What this trial is testing

Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Biogen 900
Not applicableStudy completedNCT01909492
What this trial is testing

Measurement of Relaxin Peptide in Multiple Sclerosis (MS)

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Providence Health & Services 30
Not applicableUnknownNCT02117375
What this trial is testing

EMISEP : Early Spinal Cord Lesions and Late Disability in Relapsing Remitting Multiple Sclerosis Patients

Who this might be right for
Multiple Sclerosis
Rennes University Hospital 115
Early research (Phase 1)Active Not RecruitingNCT06430671
What this trial is testing

Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis

Who this might be right for
Relapsing-remitting Multiple Sclerosis (RRMS)
Cellerys AG 11
Large-scale testing (Phase 3)Looking for participantsNCT04047628
What this trial is testing

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Who this might be right for
Relapsing Multiple SclerosisRelapsing Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis
National Institute of Allergy and Infectious Diseases (NIAID) 156
Not applicableStudy completedNCT02159573
What this trial is testing

Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 530
Load More Results